New Treatments & Clinical Trials for Osteosarcoma

Osteosarcoma is a rare bone cancer that most often affects teenagers and young adults, typically forming near the growth plates in the arm or leg. Standard treatment combines chemotherapy and surgery, and about 70% of people with localized disease survive long-term. Research focuses on improving outcomes for metastatic disease and tumors that don't respond well to chemotherapy.

What's actually going on in research

Trials are testing immunotherapies including checkpoint inhibitors and CAR T-cell therapy, newer chemotherapy combinations to overcome resistance, and targeted drugs against specific mutations found in some osteosarcomas. Researchers are also studying mifamurtide, an immune stimulant approved in Europe but not yet in the US, and ways to predict which tumors will respond poorly to standard treatment.

What to know before you search

Eligibility typically depends on whether the cancer is newly diagnosed or recurrent, whether it has spread to the lungs or other sites, and how the tumor responded to prior chemotherapy.

What types of trials are currently open

• Chemotherapy trials — Testing new drug combinations or schedules, often comparing them to standard regimens of methotrexate, doxorubicin, and cisplatin.
• Immunotherapy trials — Testing checkpoint inhibitors, CAR T-cells, or other immune-based treatments for osteosarcoma that has spread or returned after standard therapy.
• Targeted therapy trials — Testing drugs aimed at specific mutations or proteins found in some osteosarcomas, such as drugs targeting mTOR or growth factor pathways.
• Surgery timing trials — Studying the optimal timing and extent of surgery in relation to chemotherapy to maximize limb preservation and survival.
• Biomarker studies — Collecting tumor and blood samples to identify which patients are most likely to benefit from specific treatments.